# Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

> **NCT02204033** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 33 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** 99mTc - labelled hMAb BIWA 4
- **DRUG:** 186 Re - labelled hMAb BIWA 4
- **DRUG:** unlabelled hMAb BIWA 4 - low dose
- **DRUG:** unlabelled hMAb BIWA 4 - medium dose
- **DRUG:** unlabelled hMAb BIWA 4 - high dose

## Key facts

- **NCT ID:** NCT02204033
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2001-06
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204033, "Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02204033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*